Skip to main content

Table 1 Clinical characteristics of the patients with CN-AML according to their TIGAR expression levels

From: TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia

 

TIGARhigh

TIGARlow

P

Age (years), median (range)

49 (15–80)

47 (12–86)

0.798

Gender, male/female

29/29

28/30

1.000

WBC, median (range) (×109/L)

26 (0.6–291)

34 (1.3–299)

0.995

Hb, median (range) (g/L)

79 (39–154)

87 (39–148)

0.398

PLT, median (range) (×109/L)

42 (10–190)

37 (2–295)

0.190

PB blasts (%), median (range)

66 (0–98)

65 (0–96)

0.525

BM blasts (%), median (range)

75 (11.6–96.2)

72 (24–93.6)

0.870

NPM1 (+)

25.0% (12/48)

22.0% (11/50)

0.726

CEBPA (+)

14.6% (7/48)

31.9% (15/47)

0.045

FLT3-ITD (+)

12.5% (6/48)

15.7% (8/51)

0.649

C-KIT (+)

6.3 (3/48)

6.3% (3/48)

1.000

p53 mutation

2.1% (1/48)

2.0%(1/51)

1.000

  1. BM bone marrow, Hb hemoglobin, PB peripheral blood, PLT platelets, WBC white blood cells